1st Cushing’s patient dosed in ST-002 Phase 2 clinical trial
The first participant has been dosed in a Phase 2 clinical trial testing ST-002 in people with Cushing’s syndrome and high blood sugar levels. “ST-002 has the potential to change the treatment landscape for patients who currently have limited therapeutic options,” Manohar Katakam, PhD, CEO of treatment developer Sterotherapeutics,…